Fluasterone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Fluasterone
Accession Number
DB06250
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • HE 2500
Categories
UNII
R7M5UGD04G
CAS number
112859-71-9
Weight
Average: 290.422
Monoisotopic: 290.204593652
Chemical Formula
C19H27FO
InChI Key
VHZXNQKVFDBFIK-NBBHSKLNSA-N
InChI
InChI=1S/C19H27FO/c1-18-9-4-3-5-12(18)6-7-13-14(18)8-10-19(2)15(13)11-16(20)17(19)21/h6,13-16H,3-5,7-11H2,1-2H3/t13-,14+,15+,16-,18+,19+/m1/s1
IUPAC Name
(1S,2R,10R,11S,13R,15S)-13-fluoro-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-en-14-one
SMILES
C[C@]12CC[C@H]3[C@@H](CC=C4CCCC[C@]34C)[C@@H]1C[C@@H](F)C2=O

Pharmacology

Indication

Investigated for use/treatment in psoriasis and psoriatic disorders, hyperlipidemia, metabolic disease, cancer/tumors (unspecified), and obesity.

Pharmacodynamics
Not Available
Mechanism of action

Fluasterone is a synthetically stable adrenocortical steroid fluorinated analogue of dehydroepiandrosterone (DHEA), a powerful anti-inflammatory molecule with androgenic or estrogenic side effects. It is proposed that fluasterone inhibits NF-kB activation and reduces oxidative stress, but other mechanisms may play a role. Fluasterone suppresses inflammation and is effective in preclinical models of chronic inflammatory disease including psoriasis, asthma, rheumatoid arthritis, multiple sclerosis and lupus erythematosus. Fluasterone has anti-inflammatory effects inpreclinical models of chronic inflammatory disease including psoriasis, asthma, rheumatoid arthritis, multiple sclerosis and lupus erythematosus. [Aeson Pharmaceuticals Executive Report]

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AldosteroneThe risk or severity of edema formation can be increased when Fluasterone is combined with Aldosterone.
Beclomethasone dipropionateThe risk or severity of edema formation can be increased when Fluasterone is combined with Beclomethasone dipropionate.
BetamethasoneThe risk or severity of edema formation can be increased when Fluasterone is combined with Betamethasone.
Betamethasone phosphateThe risk or severity of edema formation can be increased when Fluasterone is combined with Betamethasone phosphate.
BudesonideThe risk or severity of edema formation can be increased when Fluasterone is combined with Budesonide.
Capromab pendetideFluasterone may decrease effectiveness of Capromab pendetide as a diagnostic agent.
CiclesonideThe risk or severity of edema formation can be increased when Fluasterone is combined with Ciclesonide.
ClobetasolThe risk or severity of edema formation can be increased when Fluasterone is combined with Clobetasol.
Clocortolone acetateThe risk or severity of edema formation can be increased when Fluasterone is combined with Clocortolone acetate.
CloprednolThe risk or severity of edema formation can be increased when Fluasterone is combined with Cloprednol.
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
118130
Wikipedia
Fluasterone

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00261 mg/mLALOGPS
logP4.76ALOGPS
logP4.77ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)16.48ChemAxon
pKa (Strongest Basic)-8.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area17.07 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity82.79 m3·mol-1ChemAxon
Polarizability33.22 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Classification
Not classified

Drug created on March 19, 2008 10:19 / Updated on November 02, 2018 06:15